Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Chemomab Therapeutics Ltd.CMMB · Entity 7653 | Executive VP, CFO & COO | March 16, 2022 | June 21, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Chemomab Therapeutics Ltd.
Report date March 16, 2022 · Filed June 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 2,000 |
Last balance in matching sequence
After 2022-03-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-03-16 · Purchase · Acquired 250 · Balance 1,750 F1: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Row 2 · 2022-03-16 · Purchase · Acquired 250 · Balance 2,000 F1: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. |
| Option to Purchase American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $9.77 · Expires 2021-11-08 | Direct | 196,875 |
Reported balance
After 2021-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-08 · Grant · Acquired 196,875 · Balance 196,875 F2: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F3: The options vest and become exercisable over a period of four (4) years, with one quarter (1/4) of the options vesting on November 8, 2022 -- the first anniversary of the grant date -- and the remainder in equal amounts over the ensuing 36 monthly periods, subject to the Reporting Person's continued service. F1: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
F2: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F3: The options vest and become exercisable over a period of four (4) years, with one quarter (1/4) of the options vesting on November 8, 2022 -- the first anniversary of the grant date -- and the remainder in equal amounts over the ensuing 36 monthly periods, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2022 Filed Jun 21, 2022 10:01 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 250 | $3.25 | $812.50 |
DisclosureSEC source: 0001178913-22-002402 · ownership.xml · nonDerivative · entry 2 Marvin Donald · CIK 0001891264 · Executive VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 16, 2022 Filed Jun 21, 2022 10:01 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 250 | $3.30 | $825.00 |
DisclosureSEC source: 0001178913-22-002402 · ownership.xml · nonDerivative · entry 1 Marvin Donald · CIK 0001891264 · Executive VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 14, 2022 Filed Mar 21, 2022 10:02 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 250 | $4.20 | $1,050.00 |
DisclosureSEC source: 0001178913-22-001179 · ownership.xml · nonDerivative · entry 5 Marvin Donald · CIK 0001891264 · Executive VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 14, 2022 Filed Mar 21, 2022 10:02 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 250 | $4.10 | $1,025.00 |
DisclosureSEC source: 0001178913-22-001179 · ownership.xml · nonDerivative · entry 4 Marvin Donald · CIK 0001891264 · Executive VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 14, 2022 Filed Mar 21, 2022 10:02 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 250 | $3.90 | $975.00 |
DisclosureSEC source: 0001178913-22-001179 · ownership.xml · nonDerivative · entry 3 Marvin Donald · CIK 0001891264 · Executive VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 14, 2022 Filed Mar 21, 2022 10:02 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 250 | $3.98 | $995.00 |
DisclosureSEC source: 0001178913-22-001179 · ownership.xml · nonDerivative · entry 2 Marvin Donald · CIK 0001891264 · Executive VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| March 14, 2022 Filed Mar 21, 2022 10:02 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | PurchaseAmerican Depositary Shares | 250 | $4.00 | $1,000.00 |
DisclosureSEC source: 0001178913-22-001179 · ownership.xml · nonDerivative · entry 1 Marvin Donald · CIK 0001891264 · Executive VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 F1 · security: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| November 08, 2021 Filed Mar 21, 2022 10:02 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 196,875 | $0.00 Strike: $9.77 | $0.00 |
DisclosureSEC source: 0001178913-22-001179 · ownership.xml · derivative · entry 6 Marvin Donald · CIK 0001891264 · Executive VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,875 Underlying: American Depositary Shares · 196,875 shares Expires 2021-11-08 F2 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F3 · derivative.exercise_date: The options vest and become exercisable over a period of four (4) years, with one quarter (1/4) of the options vesting on November 8, 2022 -- the first anniversary of the grant date -- and the remainder in equal amounts over the ensuing 36 monthly periods, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
| November 08, 2021 Filed Jun 21, 2022 10:01 UTC | Chemomab Therapeutics Ltd. CMMB · Entity 7653 | GrantOption to Purchase American Depositary Shares · Derivative | 196,875 | $0.00 Strike: $9.77 | $0.00 |
DisclosureSEC source: 0001178913-22-002402 · ownership.xml · derivative · entry 3 Marvin Donald · CIK 0001891264 · Executive VP, CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,875 Underlying: American Depositary Shares · 196,875 shares Expires 2021-11-08 F2 · security: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. F3 · derivative.exercise_date: The options vest and become exercisable over a period of four (4) years, with one quarter (1/4) of the options vesting on November 8, 2022 -- the first anniversary of the grant date -- and the remainder in equal amounts over the ensuing 36 monthly periods, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.